Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The botulinum toxin has been widely applied in the treatment of functional urological diseases, such as overactive bladder, neurogenic detrusor overactivity, interstitial cystitis, and chronic pelvic pain syndrome. Evidence has shown that the botulinum toxin not only affects the release of neuropeptides from motor nerve endings, but also connects sensory nerves to the central nervous system. Inflammation in the central nervous system can be reduced after botulinum toxin treatment. The scope of therapeutic targets involves detrusor overactivity, sensory disorders, bladder pain and pelvic pain, and inflammatory disorders of the bladder, prostate, and bladder outlet. Although the actual pathophysiological mechanism of the action of the botulinum toxin has not been completely demonstrated, an anti-inflammation effect might be the predominant therapeutic mechanism for functional urological disorders such as an overactive bladder, bladder hypersensitivity, interstitial cystitis, chronic pelvic pain syndrome, chronic prostatitis, and lower urinary tract symptoms/benign prostatic hyperplasia. This Special Issue of Toxins covers the therapeutic potentials of the botulinum toxin on lower urinary tract dysfunctions, with emphasis on the mechanism of pharmacological action and clinical effects.

urethra --- onabotulinumtoxinA --- voiding --- therapeutic outcome --- lower urinary tract symptoms --- botulinum toxin --- benign prostatic hyperplasia --- prostatitis --- inflammation --- Botulinum toxin --- chronic prostatitis --- interstitial cystitis --- treatment --- bladder pain --- botulinum toxin A --- predictor --- maximal bladder capacity --- hydrodistention --- urethral sphincter --- urethral sphincter dysfunction --- urodynamics --- drug delivery --- overactive bladder --- painful bladder syndrome --- molecular mechanism --- chronic pelvic pain syndrome --- pelvic pain --- functional urology disorder --- human --- network meta-analysis --- OnabotulinumtoxinA --- peripheral tibial nerve stimulation --- sacral neuromodulation --- bladder --- sensation --- therapy --- pathophysiology --- diabetes mellitus --- mid-urethral sling --- antimuscarinics --- urinary incontinence --- functional urological disorders --- pain --- neurogenic detrusor overactivity

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Cumulating evidence shows that lifestyle factors such as physical (in)activity, stress, poor sleep, unhealthy diet, and smoking are associated with chronic pain severity and sustainment across all age categories. A paradigm shift from a tissue- and disease-based approach towards individually tailored multimodal lifestyle interventions should lead to improved outcomes and decrease the psychological and socioeconomic burden of chronic pain. Such an approach fits well into the global move towards precision pain medicine for patients with chronic pain. For these reasons, this book is dedicated to Lifestyle and Chronic Pain.

Research & information: general --- Chemistry --- back pain --- neck pain --- associates --- socio-demographic factors --- psychosocial factors --- lifestyle factors --- sleep–wake disorders --- systematic review --- headache --- cervical spine --- motion --- chronic pain --- musculoskeletal pain --- pain --- chronic low back pain --- sleep --- questionnaire --- cross-cultural validation --- patient-reported outcome measure --- postural control --- dizziness --- actigraphy --- sleep quality --- nutrition --- diet quality --- chronic non-cancer pain --- chronic pelvic pain --- endometriosis --- pelvic girdle pain --- pain management --- physical activity/exercise --- (di)stress --- diet --- smoking --- COVID-19 --- persisting symptoms --- fatigue --- nociplastic pain --- functional status --- central sensitisation --- exercise therapy --- shoulder pain --- cancer survivor --- lifestyle --- obesity --- physical activity --- stress --- perceived injustice --- opioid use --- socioeconomic factors --- psychological factors --- cancer survivors --- exercise --- low back pain --- older adults --- protein intake --- KNHANES --- exposure in vivo --- pain-related fear --- rehabilitation --- complex regional pain syndrome --- child --- adolescent --- pediatric --- insomnia --- back pain --- neck pain --- associates --- socio-demographic factors --- psychosocial factors --- lifestyle factors --- sleep–wake disorders --- systematic review --- headache --- cervical spine --- motion --- chronic pain --- musculoskeletal pain --- pain --- chronic low back pain --- sleep --- questionnaire --- cross-cultural validation --- patient-reported outcome measure --- postural control --- dizziness --- actigraphy --- sleep quality --- nutrition --- diet quality --- chronic non-cancer pain --- chronic pelvic pain --- endometriosis --- pelvic girdle pain --- pain management --- physical activity/exercise --- (di)stress --- diet --- smoking --- COVID-19 --- persisting symptoms --- fatigue --- nociplastic pain --- functional status --- central sensitisation --- exercise therapy --- shoulder pain --- cancer survivor --- lifestyle --- obesity --- physical activity --- stress --- perceived injustice --- opioid use --- socioeconomic factors --- psychological factors --- cancer survivors --- exercise --- low back pain --- older adults --- protein intake --- KNHANES --- exposure in vivo --- pain-related fear --- rehabilitation --- complex regional pain syndrome --- child --- adolescent --- pediatric --- insomnia

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

The landscape of minimally invasive urological intervention is changing. A lot of new innovations and technological developments have happened over the last 3 decades. Laparoscopy and robotic surgery have revolutionised kidney and prostate cancer treatment, with more minimally invasive procedures now being carried out than ever before. At the same time, technological advancements and the use of laser have changed the face of endourology. Several new innovative treatments are now commonplace for benign prostate enlargement (BPE). Management of prostate cancer now involves procedures such as robotic prostatectomy, brachytherapy, radiotherapy, cryotherapy and HIFU. Robotic partial nephrectomy and cryotherapy have changed the face of renal cancer. En-bloc resection of bladder cancer is challenging the traditional management of non-muscle invasive bladder cancer and becoming commonplace, while robotic cystectomy is also gaining popularity for muscle invasive bladder cancer. Newer surgical intervention related to BPE includes laser (holmium, thulium and green light), water-based treatment (Rezum, Aquablation) and other minimally invasive procedures such as prostate artery embolisation (PAE) and Urolift. Endourological procedures have incorporated newer laser types and settings such as moses technology, disposable ureteroscopes (URS) and minimisation of percutaneous nephrolithotomy (PCNL) instruments. All these technological innovations and improvements have led to shorter hospital stay, reduced cost, potential reduction in complications and improvement in the quality of life (QoL).

Medicine --- Surgery --- partial nephrectomy --- single site surgery --- sutureless --- CEUS --- contrast-enhanced ultrasound --- renal ultrasound --- image quality --- small renal mass (3–5) --- kidney stones --- metabolic syndrome --- urolithiasis --- nephrolithiasis --- kidney calculi --- diabetes mellitus --- acute kidney injury --- percutaneous nephrolithotomy --- urology --- artificial intelligence --- machine learning --- urinary incontinence --- kidney stone disease --- fertility --- reproductive urology --- renal cell carcinoma --- hydronephrosis --- urinary reflux --- endourology --- pediatric urology --- prostate cancer --- bladder cancer --- nephrostomy --- quality of life --- survival --- decision making --- ureteroscopy --- laser --- RIRS --- Moses --- holmium --- mineral water --- mineral composition --- drinking water --- still water --- sparkling water --- Ho:YAG laser --- thulium fiber laser --- laser fiber --- lithotripsy --- chronic prostatitis --- chronic pelvic pain syndrome --- extracorporeal shockwave therapy --- ESWT --- NIH-CPSI --- EHS --- IIEF-5 --- QoL --- urosepsis --- laser lithotripsy --- predictor factors --- PCNL --- renal tumour --- AI --- TFL

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

Cumulating evidence shows that lifestyle factors such as physical (in)activity, stress, poor sleep, unhealthy diet, and smoking are associated with chronic pain severity and sustainment across all age categories. A paradigm shift from a tissue- and disease-based approach towards individually tailored multimodal lifestyle interventions should lead to improved outcomes and decrease the psychological and socioeconomic burden of chronic pain. Such an approach fits well into the global move towards precision pain medicine for patients with chronic pain. For these reasons, this book is dedicated to Lifestyle and Chronic Pain.

back pain --- neck pain --- associates --- socio-demographic factors --- psychosocial factors --- lifestyle factors --- sleep–wake disorders --- systematic review --- headache --- cervical spine --- motion --- chronic pain --- musculoskeletal pain --- pain --- chronic low back pain --- sleep --- questionnaire --- cross-cultural validation --- patient-reported outcome measure --- postural control --- dizziness --- actigraphy --- sleep quality --- nutrition --- diet quality --- chronic non-cancer pain --- chronic pelvic pain --- endometriosis --- pelvic girdle pain --- pain management --- physical activity/exercise --- (di)stress --- diet --- smoking --- COVID-19 --- persisting symptoms --- fatigue --- nociplastic pain --- functional status --- central sensitisation --- exercise therapy --- shoulder pain --- cancer survivor --- lifestyle --- obesity --- physical activity --- stress --- perceived injustice --- opioid use --- socioeconomic factors --- psychological factors --- cancer survivors --- exercise --- low back pain --- older adults --- protein intake --- KNHANES --- exposure in vivo --- pain-related fear --- rehabilitation --- complex regional pain syndrome --- child --- adolescent --- pediatric --- insomnia

Choose an application

• Reference Manager
• EndNote
• RefWorks (Direct export to RefWorks)

This book collects 25 scientific articles from laboratories around the world, all of which use botulinum neurotoxins as the main protagonists of their studies. The use of botulinum neurotoxin in medicine, following its ability to inhibit the effects of various disorders of different etiology on the human organism, constitutes the main topic of each article presented here. This book, which is aimed at both students and medical professionals, attempts to summarize current knowledge about the use of botulinum toxin as a therapeutic agent in many diseases, ranging from spasticity to tremor, form motor dysfunction after stroke to neuropathic pain, from hyperactive muscle to migraine, and so on. Thanks to its simplified writing, accessible to an audience who may not be familiar with the mysteries of science, readers will get new insights into this biological toxin and its multiple applications, not simply relegated to its historical use to correct of face wrinkles. Both review and research articles are presented, not only concerning animal studies, but also clinical reports. This book will provide an up-to-date picture of the state-of-the-art of the possible development of novel applications of botulinum neurotoxins for future therapeutic purposes.

Medicine --- botulinum toxin --- limb tremors --- muscle selection --- biological effect --- various cell types --- neurotransmitter --- dermatology --- novel indication --- botulinum neurotoxin --- masticatory system --- maxillofacial bone --- dental occlusion --- orthognathic surgery --- sialorrhoea --- drooling --- salivary glands --- swallowing --- eccrine glands --- onabotulinumtoxin A --- incobotulinumtoxin A --- botulinum neurotoxins --- botulinum neurotoxin serotype A --- heavy chain --- botulinum neurotoxin serotype a heavy chain (BoNT/A HC) --- spinal cord injury (SCI) --- nerve regeneration --- growth associated protein 43 (GAP-43) --- superior cervical ganglion 10 (SCG10) --- neuronal processes --- neural regeneration --- Schwann cells --- glia --- spinal cord --- immunohistochemistry --- allodynia --- weight bearing --- sciatic static index --- walking track analysis --- itch --- SNARE --- VAMP --- mast cells --- compound 48/80 --- chloroquine --- spasticity --- botulinum toxin type A --- appropriate treatment --- Therapeutic Index --- pruritus --- antipruritic --- clinical --- experimental --- BoNT/A --- astroglia --- interleukins --- microglia --- TLR2 --- TLR4 --- Snap-23 --- pain --- cerebral palsy --- botulinum toxin A --- complex regional pain syndrome --- lumbar sympathetic ganglion block --- chronic pelvic pain --- overactive detrusor --- vaginism --- temporomandibular joint dislocation --- lateral pterygoid muscle --- botulinum toxin therapy --- synaptic transmission --- SNAP-25 --- epilepsy --- Parkinson's disease --- neurotransmission blockade --- electrical activity --- prion disease --- new indications --- formulation --- delivery --- refractory chronic migraine --- tension headache --- medication overuse headache --- prophylactic treatment --- XEOMIN® --- BTX --- central neuropathic pain --- spinal cord injury --- post-stroke shoulder pain --- mouse test --- Clostridium tetani --- botulinum antitoxin --- food safety --- abobotulinumtoxinA --- upper limb spasticity --- post-stroke --- early use --- ONTIME --- clinical trial --- human --- urodynamics --- botulinum neurotoxin-A --- basal ganglia --- interspecies differences in motor behavior --- mouse --- rat --- interneurons --- hand tremor --- treatment --- electromyography --- kinematics --- essential tremor --- dystonic tremor --- tremor --- movement disorders --- Botulinum toxin --- upper limb biomechanics --- joint biomechanics --- diagnostic guidance --- clinical decision support --- spastic paresis --- electrical stimulation --- stroke management --- rehabilitation --- hand --- botulinum toxin --- limb tremors --- muscle selection --- biological effect --- various cell types --- neurotransmitter --- dermatology --- novel indication --- botulinum neurotoxin --- masticatory system --- maxillofacial bone --- dental occlusion --- orthognathic surgery --- sialorrhoea --- drooling --- salivary glands --- swallowing --- eccrine glands --- onabotulinumtoxin A --- incobotulinumtoxin A --- botulinum neurotoxins --- botulinum neurotoxin serotype A --- heavy chain --- botulinum neurotoxin serotype a heavy chain (BoNT/A HC) --- spinal cord injury (SCI) --- nerve regeneration --- growth associated protein 43 (GAP-43) --- superior cervical ganglion 10 (SCG10) --- neuronal processes --- neural regeneration --- Schwann cells --- glia --- spinal cord --- immunohistochemistry --- allodynia --- weight bearing --- sciatic static index --- walking track analysis --- itch --- SNARE --- VAMP --- mast cells --- compound 48/80 --- chloroquine --- spasticity --- botulinum toxin type A --- appropriate treatment --- Therapeutic Index --- pruritus --- antipruritic --- clinical --- experimental --- BoNT/A --- astroglia --- interleukins --- microglia --- TLR2 --- TLR4 --- Snap-23 --- pain --- cerebral palsy --- botulinum toxin A --- complex regional pain syndrome --- lumbar sympathetic ganglion block --- chronic pelvic pain --- overactive detrusor --- vaginism --- temporomandibular joint dislocation --- lateral pterygoid muscle --- botulinum toxin therapy --- synaptic transmission --- SNAP-25 --- epilepsy --- Parkinson's disease --- neurotransmission blockade --- electrical activity --- prion disease --- new indications --- formulation --- delivery --- refractory chronic migraine --- tension headache --- medication overuse headache --- prophylactic treatment --- XEOMIN® --- BTX --- central neuropathic pain --- spinal cord injury --- post-stroke shoulder pain --- mouse test --- Clostridium tetani --- botulinum antitoxin --- food safety --- abobotulinumtoxinA --- upper limb spasticity --- post-stroke --- early use --- ONTIME --- clinical trial --- human --- urodynamics --- botulinum neurotoxin-A --- basal ganglia --- interspecies differences in motor behavior --- mouse --- rat --- interneurons --- hand tremor --- treatment --- electromyography --- kinematics --- essential tremor --- dystonic tremor --- tremor --- movement disorders --- Botulinum toxin --- upper limb biomechanics --- joint biomechanics --- diagnostic guidance --- clinical decision support --- spastic paresis --- electrical stimulation --- stroke management --- rehabilitation --- hand